Selexipag (ACT-293987 NS-304) is a drug currently in development by Actelion as a treatment of pulmonary arterial hypertension. Selexipag and its active metabolite ACT-333679 are agonists at the PGI2 prostaglandin receptor which leads to vasodilation in the pulmonary circulation.
This page contains content from the copyrighted Wikipedia article "Selexipag"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
